Current Topics in iPSCs provides a deep analysis of the underlying fundamentals that support short and mid-term developments and milestones in the business of mesenchymal stem cell therapies. This volume explores the next frontier of MSC therapies and how the transformational potential of therapeutic adult cells will be realised in all therapy areas. The impacts of clinical and economic benefits are dissected throughout each of the chapters. Written by thought leaders in the field for those curious about the interface of science and business.
1. Current Topics in iPSCs Technology - p. ii 2. Cover - p. ii 3. Advances in Stem Cell Biology - p. ii 4. Title Page - p. iii 5. Copyright Page - p. iv 6. Table Of Contents - p. iv 7. Dedication - p. v 8. Contributors - p. xix 9. About the editor - p. xxv 10. Preface - p. xxvii 11. Acknowledgment - p. xxix 12. Chapter 1 Regulatory and policy considerations in iPSC research - p. 1 13. Chapter 2 hiPSCs for population genetics - p. 19 14. Chapter 3 Using human induced pluripotent stem cells to advance personalized/precision medicine - p. 45 15. Chapter 4 hiPSC disease modeling with 3D organoids - p. 63 16. Chapter 5 The differentiation of embryonic stem cells and induced pluripotent stem cells into airway and alveolar epithelial cells - p. 95 17. Chapter 6 Transplantation of human iPSC-derived kidney organoids - p. 129 18. Chapter 7 An update on clinical applications of iPSCs from a genomic point of view - p. 147 19. Chapter 8 Replication-associated DNA damage in induced pluripotent stem cells - p. 177 20. Chapter 9 Epigenetic modifications in induced pluripotent stem cells to boost myogenic commitment - p. 197 21. Chapter 10 Applications for induced pluripotent stem cells in reproductive medicine - p. 225 22. Chapter 11 iPSCs in insulin resistance, type 2 diabetes, and the metabolic syndrome - p. 275 23. Chapter 12 Induced pluripotent stem cells for cystic fibrosis - p. 303 24. Chapter 13 Exploring 15q13.3 copy number variants in iPSCs - p. 333 25. Chapter 14 Human induced pluripotent stem cells for modeling Brugada syndrome - p. 361 26. Chapter 15 iPSCs for erythromycin arrhythmogenicity testing - p. 373 27. Chapter 16 Therapeutic potential of induced pluripotent stem cell–derived extracellular vesicles - p. 393 28. Chapter 17 Proteomic approach for creation of the protein marker panels to control the quality of human induced pluripotent stem cells - p. 451 29. Chapter 18 Application of induced pluripotent stem cells in tissue engineering - p. 483 30. Chapter 19 Induced pluripotent stem cell–derived extracellular vesicles in regenerative medicine - p. 507 31. Chapter 20 iPSCs and toxicology - p. 529 32. Chapter 21 Rejuvenation through iPSCs and reprogramming in vivo and in vitro - p. 571 33. Index - p. 589 34. Index - Continued - p. 603
Current Topics in iPSCs provides a deep analysis of the underlying fundamentals that support short and mid-term developments and milestones in the business of mesenchymal stem cell therapies. This volume explores the next frontier of MSC therapies and how the transformational potential of therapeutic adult cells will be realised in all therapy areas. The impacts of clinical and economic benefits are dissected throughout each of the chapters. Written by thought leaders in the field for those curious about the interface of science and business.
1. Current Topics in iPSCs Technology - p. ii 2. Cover - p. ii 3. Advances in Stem Cell Biology - p. ii 4. Title Page - p. iii 5. Copyright Page - p. iv 6. Table Of Contents - p. iv 7. Dedication - p. v 8. Contributors - p. xix 9. About the editor - p. xxv 10. Preface - p. xxvii 11. Acknowledgment - p. xxix 12. Chapter 1 Regulatory and policy considerations in iPSC research - p. 1 13. Chapter 2 hiPSCs for population genetics - p. 19 14. Chapter 3 Using human induced pluripotent stem cells to advance personalized/precision medicine - p. 45 15. Chapter 4 hiPSC disease modeling with 3D organoids - p. 63 16. Chapter 5 The differentiation of embryonic stem cells and induced pluripotent stem cells into airway and alveolar epithelial cells - p. 95 17. Chapter 6 Transplantation of human iPSC-derived kidney organoids - p. 129 18. Chapter 7 An update on clinical applications of iPSCs from a genomic point of view - p. 147 19. Chapter 8 Replication-associated DNA damage in induced pluripotent stem cells - p. 177 20. Chapter 9 Epigenetic modifications in induced pluripotent stem cells to boost myogenic commitment - p. 197 21. Chapter 10 Applications for induced pluripotent stem cells in reproductive medicine - p. 225 22. Chapter 11 iPSCs in insulin resistance, type 2 diabetes, and the metabolic syndrome - p. 275 23. Chapter 12 Induced pluripotent stem cells for cystic fibrosis - p. 303 24. Chapter 13 Exploring 15q13.3 copy number variants in iPSCs - p. 333 25. Chapter 14 Human induced pluripotent stem cells for modeling Brugada syndrome - p. 361 26. Chapter 15 iPSCs for erythromycin arrhythmogenicity testing - p. 373 27. Chapter 16 Therapeutic potential of induced pluripotent stem cell–derived extracellular vesicles - p. 393 28. Chapter 17 Proteomic approach for creation of the protein marker panels to control the quality of human induced pluripotent stem cells - p. 451 29. Chapter 18 Application of induced pluripotent stem cells in tissue engineering - p. 483 30. Chapter 19 Induced pluripotent stem cell–derived extracellular vesicles in regenerative medicine - p. 507 31. Chapter 20 iPSCs and toxicology - p. 529 32. Chapter 21 Rejuvenation through iPSCs and reprogramming in vivo and in vitro - p. 571 33. Index - p. 589 34. Index - Continued - p. 603
